Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin plus durvalumab for HER2-overexpressing cholangiocarcinoma
ChiCTR2200065807Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Nov 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of disitamab vedotin and durvalumab in cholangiocarcinoma (CCA) and biliary cancer (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Objective response rate. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
disitamab vedotindurvalumab
03
Conditions
cholangiocarcinoma (CCA)biliary cancer
Beyond the preview
Go deeper on ChiCTR2200065807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065807.